|
Jul 29
|
RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES IN THE FIRST HALF OF 2025 REVENUE +11.7%, EBITDA(1) +9.6%, ADJUSTED NET INCOME(2) +8.9%
|
|
Jul 24
|
European Value Stocks That Could Be Trading Below Their Estimated Worth In July 2025
|
|
Apr 17
|
3 European Stocks Estimated To Be Trading At Discounts Of Up To 40.1%
|
|
Apr 16
|
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME
|
|
Oct 4
|
Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For $825M Upfront To Italian Firm Recordati
|
|
Oct 4
|
Sanofi’s rare disease drug finds yet another home
|
|
Oct 4
|
Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo
|
|
Oct 4
|
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE
|
|
Jun 18
|
KKR, TPG Express Interest in Italian Drugmaker Recordati
|